The Rbf-1 antibody targets the Retinoblastoma (RB1) protein, a critical tumor suppressor encoded by the RB1 gene. This protein regulates cell cycle progression by controlling the G1/S transition through interactions with E2F transcription factors . In Drosophila, the ortholog RBF1 shares functional conservation with mammalian RB1, participating in chromatin organization, metabolic regulation, and apoptosis . Rbf-1 antibodies are indispensable tools for studying these processes across model organisms and human pathologies, particularly in cancer research.
Condensin II Interaction: RBF1 interacts with dCAP-D3 (Condensin II subunit) to promote chromatin condensation during mitosis. Anti-Rbf1 antibodies revealed RBF1’s E2F-independent role in targeting Condensin II to DNA, a mechanism conserved in mammals .
Transcriptional Repression: Immunoprecipitation studies show RB1 recruits histone deacetylases (HDACs) and SWI/SNF complexes to silence E2F target genes .
Drosophila Tumor Models: Anti-Rbf antibodies identified synthetic lethal (SL) partners of RB1 in a Drosophila eye model. Targeting these SL genes (e.g., Pten, Ras) suppressed tumor growth in combinatorial mutants .
Clinical Relevance: Low expression of RB1 SL genes correlates with improved survival in RB1-deficient human cancers .
Glutamine Dependency: RBF1 depletion in Drosophila alters glutamine catabolism, elevating dNTP synthesis and oxidative stress. Anti-Rbf1 staining confirmed protein loss in larval tissues, linking RB1 to metabolic adaptation in fasting conditions .
Pro-Apoptotic Role: Rbf1/dE2F2 complexes repress anti-apoptotic genes (buffy, diap1). Antibody-based assays demonstrated Rbf1’s post-transcriptional regulation of diap1 mRNA stability .
Antimicrobial Peptide Regulation: RBF1 and dCAP-D3 co-regulate immune genes in Drosophila fat cells, revealed by ChIP-seq and RNAi .